Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New AI tool aims to help doctors Fine-Tune diabetes treatment

NCT ID NCT07063420

Disease control Sponsor: Daniel Chernavvsky, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a decision support system (software) that helps healthcare providers choose the best combination of diabetes drugs for people with type 2 diabetes who use insulin. The study will enroll 18 adults and compare blood sugar control using continuous glucose monitors with and without the software. The goal is to see if the tool improves glycemic outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Decision support system software
What this could lead to
If successful, this could help doctors better manage insulin and other diabetes medications, leading to improved blood sugar control for patients.
What could go wrong
This is a very small pilot study with only 18 participants, so results may not apply to everyone. The software is still experimental and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18.0 years old at time of consent. 2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months. 3. Hemoglobin A1c (HbA1c) ≥ 7.0%. 4. Currently using an approved long-acting insulin for at least 3 months (e.g., insulin glargine, insulin degludec). 5. Treated or about to be treated with multi-drug therapies for T2D. 6. If using a CGM, willingness to wear an additional study CGM during the duration of the study. 7. Access to the internet and willingness to upload data during the study as needed. 8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females who self-report that they are of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. Exclusion Criteria: 1. Currently using rapid insulin for at least three months (e.g., insulin aspart, insulin lispro, insulin regular). 2. Currently being treated for a seizure disorder. 3. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples: 1. Seizure disease 2. Decompensated cardiac disease 4. Inpatient psychiatric treatment in the past 6 months 5. Presence of a known adrenal disorder 6. Currently pregnant or intent to become pregnant during the trial. 7. Anticipated surgical, interventional procedures or prolonged periods of fasting during this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes treated with insulin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes treated with insulin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Virginia Center for Diabetes Technology

    RECRUITING

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.